[S,S]-Reboxetine Add-On Trial

• Status: Terminated
• Trial end date: 2007-10-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with [S,S]-Reboxetine against pregabalin monotherapy in patients with PHN

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin; Reboxetine

Criteria

Inclusion Criteria:

• Patients must have pain present for more than 3 months after the healing of shingles skin rash

• Patients at screening must have a score >/=40 mm on the pain visual analogue scale

Exclusion Criteria:

• Patients with significant renal and hepatic impairment

• Patients with other severe pain, that may impair the self-assessment of the pain due to shingles

• Patients with clinically abnormal electrocardiogram